ST吉药(300108) - 2018 Q4 - 年度财报

Financial Performance - The company's operating revenue for 2018 was ¥942,251,629.65, representing a 34.52% increase compared to ¥700,439,094.96 in 2017[26]. - The net profit attributable to shareholders for 2018 was ¥216,659,914.80, a 7.01% increase from ¥202,464,046.01 in 2017[26]. - The net profit attributable to shareholders after deducting non-recurring gains and losses decreased by 54.49% to ¥45,166,422.57 from ¥99,239,185.54 in 2017[26]. - The total assets at the end of 2018 reached ¥4,852,817,985.94, a 53.83% increase from ¥3,154,645,192.98 at the end of 2017[26]. - The basic earnings per share for 2018 was ¥0.33, a 3.13% increase from ¥0.32 in 2017[26]. - The total profit amounted to ¥283,721,054.24, which is an increase of 11.71% compared to the previous year[57]. - The pharmaceutical sector contributed ¥726,810,929.68, accounting for 77.14% of total revenue, with a year-on-year increase of 4.73%[61]. - The chemical sector generated ¥215,440,699.97, making up 22.86% of total revenue, but saw a decline of 4.73% compared to the previous year[61]. - The gross profit margin for the pharmaceutical industry was 33.46%, down 7.76% from the previous year[63]. Operational Challenges - The company is facing increased operational risks due to rising labor and logistics costs, as well as intensified global competition in the pharmaceutical industry[9]. - New drug development is subject to higher evaluation costs and longer approval times, which may impact profitability and operational costs[10]. - The company emphasizes strict adherence to national policies in drug development to mitigate risks associated with long and unpredictable approval cycles[11]. - The company is actively monitoring industry policy changes to manage and reduce operational risks[9]. - The company has experienced significant increases in marketing and management expenses due to competitive pressures in the pharmaceutical sector[9]. - The company is focused on addressing the challenges posed by intensified competition in the chemical industry, which may affect revenue and profitability[13]. Investment and Acquisitions - The company reported a goodwill amount of ¥854,054,756.79 from acquisitions, including Jinbao Pharmaceutical and Liaoning Meiluo, which may face impairment risks if the acquired assets' performance deteriorates[12]. - The company acquired a 70% stake in Yuanda Kanghua for zero price, enhancing its distribution network in Beijing, Tianjin, and Hebei, with over 1,500 terminal sales clients[42]. - The company purchased a 70% stake in Meiluo Pharmaceutical for 28 million RMB, expanding its distribution capabilities in Liaoning Province[43]. - The company invested 230 million RMB to acquire 100% of Yalida Gelatin Capsule Co., which has an annual production capacity of 20 billion capsules and an annual output value of 200 million RMB[44]. - The company acquired 99.68% of Changchun Puhua Pharmaceutical for approximately 618 million RMB, integrating its operations and expanding its product offerings in various medical fields[45]. - The company completed the acquisition of 70% of Liaoning Meiluo Pharmaceutical Co., Ltd. for a total cash consideration of RMB 28 million[111]. Research and Development - The company is committed to improving its new drug project management and cultivating skilled talent to enhance R&D outcomes[11]. - The company is currently developing 6 new national drugs, including 2 active pharmaceutical ingredients[37]. - The company has several ongoing drug development projects, including "Ribavirin dispersible tablets" and "Methylsulfonylmethane" raw materials, with clinical trials currently in progress[53]. - R&D expenses rose by 48.58% to ¥14,844,244.90, primarily due to increased investment in the development of Respite and subsidiary acquisitions[71]. - R&D investment accounted for 1.89% of operating revenue, down from 2.89% the previous year[74]. - The number of R&D personnel increased to 139, representing 9.00% of the total workforce[72]. Corporate Governance and Compliance - The company has established a sound internal management and control system to enhance governance and protect shareholder rights[152]. - The company has made significant accounting policy changes, including adjustments to the presentation of receivables and payables, impacting various financial statement line items[119]. - The company reported no non-operating fund occupation by controlling shareholders or related parties during the reporting period[117]. - The company has not violated any commitments made during the asset restructuring process, ensuring compliance with all obligations[110]. - The company has implemented an employee stock incentive plan, granting 30 million restricted shares to 33 individuals, representing 1.8018% of the total share capital[132]. Market Strategy and Future Plans - The company plans to not distribute cash dividends or issue bonus shares, indicating a focus on reinvestment[14]. - Future strategies include expanding into new markets and enhancing product offerings, particularly in health and cosmetic sectors[89]. - The strategic focus includes expanding into the OTC market and enhancing the development of innovative drugs[97]. - The company aims to strengthen group management and deepen the breadth and depth of chain and terminal sales[97]. - The company is leveraging resources from the Changbai Mountain traditional Chinese medicine industry to develop a health industry[97]. Employee and Shareholder Information - The total number of employees in the company is 1,544, with 6 in the parent company and 1,538 in major subsidiaries[196]. - The actual remuneration paid to the board of directors, supervisors, and senior management in 2018 was 1.696 million yuan[191]. - The company has a total of 14 directors, supervisors, and senior management personnel[191]. - The total number of shareholders at the end of the reporting period was 14,590, an increase from 12,569 at the end of the previous month[167]. - The company has a total of 1,918,033 shares held by the current supervisor, which remains unchanged[180].